<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00660517</url>
  </required_header>
  <id_info>
    <org_study_id>MP4001</org_study_id>
    <nct_id>NCT00660517</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies</brief_title>
  <official_title>Randomized, Double-Blind Trial of MP29-02 Nasal Spray Compared to Placebo, Astelin Nasal Spray, and Fluticasone Propionate Nasal Spray in the Treatment of Patients With Seasonal Allergic Rhinitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Meda Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Meda Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if two allergy medications (azelastine and
      fluticasone) are more effective than placebo or either medication alone (azelastine or
      fluticasone)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a Phase III, randomized, double-blind, parallel-group study in subjects with
      moderate-to-severe SAR. The study will be conducted at 8 investigational sites during the
      2007-2008 Texas Mountain Cedar allergy season. After a 7-day Placebo Lead-In Period (Day -7
      to Day 1), subjects will be instructed to take placebo lead-in medication twice daily (1
      spray per nostril), approximately every 12 hours. On Day 1, subjects who satisfy the symptom
      severity requirements and continue to meet all of the study inclusion/exclusion criteria will
      be randomized in a 1:1:1:1 ratio to receive 1 spray per nostril twice daily of MP29-02,
      azelastine hydrochloride, fluticasone propionate, or placebo nasal spray.

      Efficacy will be assessed by the change from baseline in the subject-reported 12-hour
      reflective Total Nasal Symptom Score (TNSS), consisting of the sum of the scores of sneezing,
      nasal congestion, runny nose, and nasal itching. On Days -7 through 14, subjects will rate
      the TNSS symptoms, the TOSS symptoms of itchy eyes, watery eyes and eye redness, and the
      symptom of postnasal drip twice daily (AM and PM) in a diary prior to the dose of study
      medication. Symptoms will be scored on a 0 to 3 scale (0 = no symptoms, 1 = mild symptoms, 2
      = moderate symptoms, 3 = severe symptoms), such that the maximum daily symptom severity score
      will be 24 for the TNSS and 18 for the TOSS. The 12-hour reflective TNSS, the instantaneous
      TNSS, the 12-hour reflective score for postnasal drip, the 12-hour reflective TOSS, and the
      instantaneous TOSS will be calculated based on these scores. Additional secondary efficacy
      variables will include reflective and individual nasal and ocular symptom scores and change
      from Baseline to Day 14 in the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ).

      Subjects â‰¥ 18 years of age will complete the adult RQLQ on Day 1 (prior to dosing) and Day
      14. Subjects will return to the clinic on Day 7 for an interim evaluation. After completing
      the 2-week double-blind treatment period, subjects will return to the clinic on Day 14 (or at
      time of early termination) for an end-of-study evaluation. Safety and tolerability
      assessments will be made on Days 7 and 14. Tolerability will be evaluated by subject reported
      adverse events (AEs), nasal examinations, and vital signs assessments.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in 12 Hour Reflective Total Nasal Symptom Score (rTNSS)</measure>
    <time_frame>day 1 to day14</time_frame>
    <description>change from baseline in the 12 hour reflective total nasal symptoms score(rTNSS) consisting of nasal congestion,runny nose,itchy nose and sneezing scored twice daily( AM and PM) in diary cards for the entire 14 day study period The measurement scale is 0 to 24.A reduction in symptom severity score is indicated by a negative value.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 12 Hour Instantaneous Total Nasal Symptom Score (iTNSS)</measure>
    <time_frame>day 1 to day 14</time_frame>
    <description>change from baseline in the 12 hour instantaneous total nasal symptoms score(iTNSS) consisting of nasal congestion,runny nose,itchy nose and sneezing scored twice daily( AM and PM) in diary cards for the entire 14 day study period.
The measurement scale is 0 to 24.A reduction in symptom severity score is indicated by a negative value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Adult ( Greater Than 18 Years of Age) Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ)at the End of 14 Days</measure>
    <time_frame>day 1 to day 14</time_frame>
    <description>Change from Baseline in adult ( greater than 18 years of age) Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ)at the end of 14 days The measurement scale is 0 to 24. A reduction in symptom severity score is indicated by a negative value.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">607</enrollment>
  <condition>Seasonal Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>MP29-02</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>azelastine HCl 548 mcg / fluticasone propionate 200 mcg nasal spray</description>
  </arm_group>
  <arm_group>
    <arm_group_label>azelastine Hcl 548 mcg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>azelastine Hcl 548 mcg nasal spray</description>
  </arm_group>
  <arm_group>
    <arm_group_label>fluticasone propionate 200 mcg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>fluticasone propionate 200 mcg nasal spray</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo nasal spray</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MP29-02</intervention_name>
    <description>azelastine HCl 548 mcg / fluticasone propionate 200 mcg nasal spray one spray per nostril twice a day</description>
    <arm_group_label>MP29-02</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>azelastine Hcl</intervention_name>
    <description>azelastine Hcl nasal spray one spray per nostril two times a day</description>
    <arm_group_label>azelastine Hcl 548 mcg</arm_group_label>
    <other_name>Astelin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluticasone propionate</intervention_name>
    <description>fluticasone propionate 200 mcg nasal spray one spray per nostril two times a day</description>
    <arm_group_label>fluticasone propionate 200 mcg</arm_group_label>
    <other_name>generic Flonase</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo nasal spray one spray per nostril two times a day</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female subjects 12 years of age and older with a 2 year history of moderate
             to severe seasonal allergic rhinitis

          -  Must be in generally good health

          -  Must meet minimum symptom requirements, as specified in the protocol.

          -  Must be willing and able to provide informed consent and to participate in all study
             procedures

          -  Positive skin test to a prevalent Texas Mountain Cedar allergen

        Exclusion Criteria:

          -  On Focused Nasal Examination, the presence of any nasal mucosal erosion, nasal
             ulceration, or nasal septal perforation (Grade 1b - 4) at either the screening visit
             or randomization visit will disqualify the subject from the study.

          -  Other nasal disease(s) likely to affect deposition of intranasal medication, such as
             sinusitis, rhinitis medicamentosa, clinically significant polyposis, or nasal
             structural abnormalities.

          -  Nasal surgery or sinus surgery within the previous year.

          -  Chronic sinusitis - more than 3 episodes per year

          -  Planned travel outside of the study area during the study period

          -  The use of any investigational drug within 30 days prior to Day screening. No
             investigational products are permitted for use during the conduct of this study

          -  Presence of any hypersensitivity to drugs similar to azelastine hydrochloride or
             fluticasone propionate

          -  Women who are pregnant or nursing

          -  Women of childbearing potential who are not abstinent or not practicing a medically
             acceptable method of contraception* see section 6.1.1

          -  Respiratory Tract Infections within 14 days prior to Day screening

          -  Respiratory Tract Infections requiring antibiotic treatment 14 days prior to screening

          -  Asthma (with the exception of mild, intermittent asthma). Subjects with mild,
             intermittent asthma who only require short-acting inhaled bronchodilators (not more
             often than twice per week) and who do not have nocturnal awakening as a result of
             asthma are eligible for enrollment

          -  Significant pulmonary disease including COPD

          -  Clinically significant arrhythmia or symptomatic cardiac conditions

          -  A known history of alcohol or drug abuse within the last 2 years

          -  Existence of any surgical or medical condition or physical or laboratory findings,
             which in the opinion of the investigator or sponsor's medical monitor, might
             significantly alter the absorption, distribution, metabolism, or excretion of study
             drug; that might significantly affect the subject's ability to complete this trial; or
             their safety in this trial.

          -  Clinically relevant abnormal physical findings within 1 week of randomization which,
             in the opinion of the investigator, would interfere with the objectives of the study
             or that may preclude compliance with the study procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lewis M Fredane, MD</last_name>
    <role>Study Director</role>
    <affiliation>Meda Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Allergy and Asthma Associates</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Texas Research</name>
      <address>
        <city>New Braunfels</city>
        <state>Texas</state>
        <zip>78130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwest Allergy and Asthma Center, P.A.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sylvana Research Associates</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy, Asthma Research Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy and Asthma Care</name>
      <address>
        <city>Waco</city>
        <state>Texas</state>
        <zip>76708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy and Asthma Center</name>
      <address>
        <city>Waco</city>
        <state>Texas</state>
        <zip>76712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 14, 2008</study_first_submitted>
  <study_first_submitted_qc>April 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 17, 2008</study_first_posted>
  <results_first_submitted>May 17, 2012</results_first_submitted>
  <results_first_submitted_qc>June 18, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 23, 2012</results_first_posted>
  <disposition_first_submitted>June 23, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>July 12, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 14, 2011</disposition_first_posted>
  <last_update_submitted>July 23, 2012</last_update_submitted>
  <last_update_submitted_qc>July 23, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 27, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis, Allergic, Seasonal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Azelastine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Azelastine HCl 548 Mcg / Fluticasone Propionate 200 Mcg</title>
          <description>azelastine Hcl/ fluticasone propionate nasal spray one spray per nostril two times a day</description>
        </group>
        <group group_id="P2">
          <title>Azelastine Hcl 548 Mcg</title>
          <description>azelastine Hcl nasal spray one spray per nostril two times a day</description>
        </group>
        <group group_id="P3">
          <title>Fluticasone Propionate 200 Mcg</title>
          <description>fluticasone propionate nasal spray one spray per nostril two times a day</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>nasal spray</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="153"/>
                <participants group_id="P2" count="152"/>
                <participants group_id="P3" count="151"/>
                <participants group_id="P4" count="151"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="145"/>
                <participants group_id="P2" count="144"/>
                <participants group_id="P3" count="144"/>
                <participants group_id="P4" count="144"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Azelastine HCl 548 Mcg / Fluticasone Propionate 200 Mcg</title>
          <description>azelastine Hcl/ fluticasone propionate nasal spray one spray per nostril two times a day</description>
        </group>
        <group group_id="B2">
          <title>Azelastine Hcl 548 Mcg</title>
          <description>azelastine Hcl nasal spray one spray per nostril two times a day</description>
        </group>
        <group group_id="B3">
          <title>Fluticasone Propionate 200 Mcg</title>
          <description>fluticasone propionate nasal spray one spray per nostril two times a day</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>nasal spray</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="153"/>
            <count group_id="B2" value="152"/>
            <count group_id="B3" value="151"/>
            <count group_id="B4" value="151"/>
            <count group_id="B5" value="607"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="136"/>
                    <measurement group_id="B2" value="132"/>
                    <measurement group_id="B3" value="137"/>
                    <measurement group_id="B4" value="131"/>
                    <measurement group_id="B5" value="536"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.5" spread="14.2"/>
                    <measurement group_id="B2" value="39.5" spread="14.1"/>
                    <measurement group_id="B3" value="38.1" spread="14.2"/>
                    <measurement group_id="B4" value="39.9" spread="14.7"/>
                    <measurement group_id="B5" value="39.2" spread="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="97"/>
                    <measurement group_id="B2" value="97"/>
                    <measurement group_id="B3" value="100"/>
                    <measurement group_id="B4" value="102"/>
                    <measurement group_id="B5" value="396"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="51"/>
                    <measurement group_id="B4" value="49"/>
                    <measurement group_id="B5" value="211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="153"/>
                    <measurement group_id="B2" value="152"/>
                    <measurement group_id="B3" value="151"/>
                    <measurement group_id="B4" value="151"/>
                    <measurement group_id="B5" value="607"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in 12 Hour Reflective Total Nasal Symptom Score (rTNSS)</title>
        <description>change from baseline in the 12 hour reflective total nasal symptoms score(rTNSS) consisting of nasal congestion,runny nose,itchy nose and sneezing scored twice daily( AM and PM) in diary cards for the entire 14 day study period The measurement scale is 0 to 24.A reduction in symptom severity score is indicated by a negative value.</description>
        <time_frame>day 1 to day14</time_frame>
        <population>Intent to Treat (ITT) population includes all subjects who were randomized and had at least one post baseline efficacy observation</population>
        <group_list>
          <group group_id="O1">
            <title>Azelastine HCl 548 Mcg / Fluticasone Propionate 200 Mcg</title>
            <description>azelastine Hcl/ fluticasone propionate nasal spray one spray per nostril two times a day</description>
          </group>
          <group group_id="O2">
            <title>Azelastine Hcl 548 Mcg</title>
            <description>azelastine Hcl nasal spray one spray per nostril two times a day</description>
          </group>
          <group group_id="O3">
            <title>Fluticasone Propionate 200 Mcg</title>
            <description>fluticasone propionate nasal spray one spray per nostril two times a day</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>nasal spray</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 12 Hour Reflective Total Nasal Symptom Score (rTNSS)</title>
          <description>change from baseline in the 12 hour reflective total nasal symptoms score(rTNSS) consisting of nasal congestion,runny nose,itchy nose and sneezing scored twice daily( AM and PM) in diary cards for the entire 14 day study period The measurement scale is 0 to 24.A reduction in symptom severity score is indicated by a negative value.</description>
          <population>Intent to Treat (ITT) population includes all subjects who were randomized and had at least one post baseline efficacy observation</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="153"/>
                <count group_id="O2" value="152"/>
                <count group_id="O3" value="151"/>
                <count group_id="O4" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.3" spread="5.1"/>
                    <measurement group_id="O2" value="-3.3" spread="4.2"/>
                    <measurement group_id="O3" value="-3.8" spread="4.8"/>
                    <measurement group_id="O4" value="-2.2" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 12 Hour Instantaneous Total Nasal Symptom Score (iTNSS)</title>
        <description>change from baseline in the 12 hour instantaneous total nasal symptoms score(iTNSS) consisting of nasal congestion,runny nose,itchy nose and sneezing scored twice daily( AM and PM) in diary cards for the entire 14 day study period.
The measurement scale is 0 to 24.A reduction in symptom severity score is indicated by a negative value.</description>
        <time_frame>day 1 to day 14</time_frame>
        <population>Intent to Treat (ITT) population includes all subjects who were randomized and had at least one post baseline efficacy evaluation</population>
        <group_list>
          <group group_id="O1">
            <title>Azelastine HCl 548 Mcg / Fluticasone Propionate 200 Mcg</title>
            <description>azelastine Hcl/ fluticasone propionate nasal spray one spray per nostril two times a day</description>
          </group>
          <group group_id="O2">
            <title>Azelastine Hcl 548 Mcg</title>
            <description>azelastine Hcl nasal spray one spray per nostril two times a day</description>
          </group>
          <group group_id="O3">
            <title>Fluticasone Propionate 200 Mcg</title>
            <description>fluticasone propionate nasal spray one spray per nostril two times a day</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>placebo nasal spray one spray per nostril two times a day</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 12 Hour Instantaneous Total Nasal Symptom Score (iTNSS)</title>
          <description>change from baseline in the 12 hour instantaneous total nasal symptoms score(iTNSS) consisting of nasal congestion,runny nose,itchy nose and sneezing scored twice daily( AM and PM) in diary cards for the entire 14 day study period.
The measurement scale is 0 to 24.A reduction in symptom severity score is indicated by a negative value.</description>
          <population>Intent to Treat (ITT) population includes all subjects who were randomized and had at least one post baseline efficacy evaluation</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="153"/>
                <count group_id="O2" value="152"/>
                <count group_id="O3" value="151"/>
                <count group_id="O4" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.4" spread="5.2"/>
                    <measurement group_id="O2" value="-3.0" spread="4.5"/>
                    <measurement group_id="O3" value="-3.5" spread="4.8"/>
                    <measurement group_id="O4" value="-1.7" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Adult ( Greater Than 18 Years of Age) Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ)at the End of 14 Days</title>
        <description>Change from Baseline in adult ( greater than 18 years of age) Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ)at the end of 14 days The measurement scale is 0 to 24. A reduction in symptom severity score is indicated by a negative value.</description>
        <time_frame>day 1 to day 14</time_frame>
        <population>Intent to Treat(ITT) population (18 years of age or older) who have had at least one post baseline efficacy evaluation</population>
        <group_list>
          <group group_id="O1">
            <title>Azelastine HCl 548 Mcg / Fluticasone Propionate 200 Mcg</title>
            <description>azelastine Hcl/ fluticasone propionate nasal spray one spray per nostril two times a day</description>
          </group>
          <group group_id="O2">
            <title>Azelastine Hcl 548 Mcg</title>
            <description>azelastine Hcl nasal spray one spray per nostril two times a day</description>
          </group>
          <group group_id="O3">
            <title>Fluticasone Propionate 200 Mcg</title>
            <description>fluticasone propionate nasal spray one spray per nostril two times a day</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>nasal spray</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Adult ( Greater Than 18 Years of Age) Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ)at the End of 14 Days</title>
          <description>Change from Baseline in adult ( greater than 18 years of age) Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ)at the end of 14 days The measurement scale is 0 to 24. A reduction in symptom severity score is indicated by a negative value.</description>
          <population>Intent to Treat(ITT) population (18 years of age or older) who have had at least one post baseline efficacy evaluation</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="133"/>
                <count group_id="O3" value="132"/>
                <count group_id="O4" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" spread="1.4"/>
                    <measurement group_id="O2" value="-1.2" spread="1.3"/>
                    <measurement group_id="O3" value="-1.4" spread="1.4"/>
                    <measurement group_id="O4" value="-1.0" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Azelastine HCl 548 Mcg / Fluticasone Propionate 200 Mcg</title>
          <description>azelastine Hcl/ fluticasone propionate nasal spray one spray per nostril two times a day</description>
        </group>
        <group group_id="E2">
          <title>Azelastine Hcl 548 Mcg</title>
          <description>azelastine Hcl nasal spray one spray per nostril two times a day</description>
        </group>
        <group group_id="E3">
          <title>Fluticasone Propionate 200 Mcg</title>
          <description>fluticasone propionate nasal spray one spray per nostril two times a day</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>nasal spray</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title vocab="medra 10.0">dysgusia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="153"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="153"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>acute sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="153"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="152"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="151"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>epistaxis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="153"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="152"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="151"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>nasal discomfort</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>dry skin</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="153"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Investigators participating in multicenter studies must agree not to present data gathered individually or by a subgroup of centers before the full, initial publication, unless this has been agreed to by all other investigators and Meda Pharmaceuticals.
Meda Pharmaceuticals requests that it receive copies of any intended communication reasonably in advance (at least 15 working days for an abstract or oral presentation and 45 working days for a manuscript)</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>David Ginsberg, D.O.</name_or_title>
      <organization>Meda Pharmaceuticals</organization>
      <phone>7325642364</phone>
      <email>david.ginsberg@meda.us</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

